BioAtla (NASDAQ:BCAB) Stock Price Down 6.1% – What’s Next?

BioAtla, Inc. (NASDAQ:BCAB) shares were down 6.1% during mid-day trading on Monday . The company traded as low as $0.48 and last traded at $0.50. Approximately 1,421,670 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 1,877,024 shares. The stock had previously closed at $0.53.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

BioAtla Stock Performance

The stock’s 50 day moving average price is $1.27 and its 200-day moving average price is $1.59. The company has a market cap of $23.30 million, a PE ratio of -0.28 and a beta of 1.17.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.12. The business had revenue of $11.00 million during the quarter. During the same period in the previous year, the company earned ($0.70) earnings per share. On average, analysts anticipate that BioAtla, Inc. will post -1.49 EPS for the current year.

Institutional Investors Weigh In On BioAtla

Institutional investors have recently bought and sold shares of the stock. Vontobel Holding Ltd. bought a new stake in BioAtla in the third quarter valued at approximately $28,000. Chicago Partners Investment Group LLC purchased a new position in shares of BioAtla in the third quarter worth $44,000. American Century Companies Inc. raised its holdings in BioAtla by 36.1% during the 2nd quarter. American Century Companies Inc. now owns 43,391 shares of the company’s stock valued at $59,000 after buying an additional 11,503 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in BioAtla during the 2nd quarter valued at $99,000. Finally, XTX Topco Ltd grew its holdings in BioAtla by 7.2% in the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock worth $273,000 after acquiring an additional 10,384 shares during the last quarter. 77.23% of the stock is currently owned by hedge funds and other institutional investors.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.